Who are Fexofenadine HCl + Pseudoephedrine HCl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): brompheniramine + phenylephrine, Brompheniramine + pseudoephedrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fexofenadine-hcl-pseudoephedrine-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fexofenadine HCl + Pseudoephedrine HCl — Competitive Intelligence Brief

Fexofenadine HCl + Pseudoephedrine HCl (Fexofenadine HCl + Pseudoephedrine HCl) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihistamine + decongestant combination. Area: Allergy/Immunology.

marketed Antihistamine + decongestant combination H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine) Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Fexofenadine HCl + Pseudoephedrine HCl (Fexofenadine HCl + Pseudoephedrine HCl) — Dr. Reddy's Laboratories Limited. Fexofenadine blocks histamine H1 receptors to reduce allergic symptoms, while pseudoephedrine acts as a sympathomimetic decongestant to relieve nasal congestion.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fexofenadine HCl + Pseudoephedrine HCl TARGET	Fexofenadine HCl + Pseudoephedrine HCl	Dr. Reddy's Laboratories Limited	marketed	Antihistamine + decongestant combination	H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine)
brompheniramine + phenylephrine	brompheniramine + phenylephrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (phenylephrine)
Brompheniramine + pseudoephedrine	Brompheniramine + pseudoephedrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihistamine + decongestant combination class)

Ache Laboratorios Farmaceuticos S.A. · 2 drugs in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fexofenadine HCl + Pseudoephedrine HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/fexofenadine-hcl-pseudoephedrine-hcl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab